FAB122

· Ferrer Internacional S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FAB122, covering 2025-03-04 to 2025-03-04. Get the full timeline:

Most recent: Clinical Trial Update: Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis [Phase 3]